GlassScriptPhysician profile
Natalia Hochbaum
NPI 1184890113
$3,234.86
in general payments reported to CMS, 2019-2025
23 companies · $602 in 2025
The $602 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $138 · 2021: $187 · 2022: $228 · 2023: $848 · 2024: $1,032 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,482.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $590.99 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Novartis Pharmaceuticals Corporation | $503.34 | 2019-2025 | |
| Irhythm Technologies, INC. | $415.63 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Abiomed | $327.42 | 2023-2024 | Impella |
| Boston Scientific Corporation | $277.25 | 2024 | |
| Paragonix Technologies, INC. | $240.81 | 2024 | Baroguard, Lungguard, Sherpapak |
| Eurofins Viracor, LLC | $236.03 | 2025 | |
| Impulse Dynamics (USA) INC. | $169.58 | 2022-2025 | Optimizer, Optimizer |
| Pfizer INC. | $81.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $58.83 | 2021-2024 | Wainua, Lokelma, Farxiga |
| Actelion Pharmaceuticals US, INC. | $45.76 | 2020-2021 | |
| Edwards Lifesciences Corporation | $34.37 | 2023 | Inspiris Resilia Aortic Valve |
| Cvrx, INC. | $31.93 | 2024 | Barostim Neo System |
| Atricure, INC. | $29.74 | 2025 | Atriclip Laa Exclusion System |
| Daxor Corporation | $28.80 | 2023 | Bva-100 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $25.36 | 2025 | Cresemba |
| Medtronic, INC. | $25.25 | 2025 | Aurora Ev-Icd Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.57 | 2022 | |
| Endotronix, INC. | $21.30 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Alnylam Pharmaceuticals INC. | $19.83 | 2024 | Amvuttra |
| Merck Sharp & Dohme LLC | $17.77 | 2025 | Verquvo |
| Invivyd INC | $15.12 | 2025 | Pemgarda |
| Amarin Pharma, INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Hochbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.